福瑞达(600223) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,482,210,648.61, representing a decrease of 13.08% compared to the same period last year[5] - The net profit attributable to shareholders was ¥66,295,134.64, down 22.74% year-on-year[5] - Basic earnings per share were ¥0.07, reflecting a decrease of 17.67%[5] - Net profit for Q1 2022 was ¥66,403,453.14, a decline of 28.49% from ¥92,736,542.99 in Q1 2021[40] - Earnings per share for Q1 2022 were ¥0.07 (basic) and ¥0.06 (diluted), compared to ¥0.085 for both in Q1 2021[40] - The company reported a total comprehensive income of ¥66,403,453.14 for Q1 2022, down from ¥92,736,542.99 in Q1 2021[40] Cash Flow - The net cash flow from operating activities was negative at ¥349,836,200.78, a decline of 240.73% compared to the previous year[5] - Cash flow from operating activities for Q1 2022 was -349,836,200.78, a decrease from 248,589,677.72 in Q1 2021, indicating a significant decline in operational cash generation[44] - Cash received from sales of goods and services in Q1 2022 was 1,849,433,506.50, down from 3,571,795,540.77 in Q1 2021, highlighting a decline in revenue generation[44] - Cash outflow for purchasing goods and services in Q1 2022 was 1,804,188,418.62, a decrease from 2,663,352,605.31 in Q1 2021, suggesting cost management efforts[44] - Cash received from other operating activities in Q1 2022 was 392,427,510.28, up from 293,837,502.80 in Q1 2021, indicating improved operational efficiency[44] - Net cash flow from financing activities for Q1 2022 was 375,034,442.92, a recovery from -1,293,164,502.63 in Q1 2021, reflecting improved financing conditions[45] - The company received 1,439,396,311.79 in cash from other financing activities in Q1 2022, significantly higher than 654,624,177.93 in Q1 2021, indicating enhanced financing activities[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥61,638,844,811.82, showing a slight increase of 0.36% from the previous year[8] - The company’s total liabilities as of March 31, 2022, were CNY 55.02 billion, compared to CNY 55.34 billion at the end of 2021[32] - Total liabilities as of March 31, 2022, were ¥55,090,016,431.00, slightly up from ¥54,915,669,576.75 as of December 31, 2021[33] - The company’s equity attributable to shareholders was CNY 4.78 billion as of March 31, 2022, compared to CNY 4.77 billion at the end of 2021[24] - Total equity attributable to shareholders as of March 31, 2022, was ¥4,775,079,191.66, an increase from ¥4,727,128,835.89 as of December 31, 2021[33] Segment Performance - The pharmaceutical segment reported revenue of CNY 90 million in Q1 2022, a decrease of 25.74% year-on-year, with a gross margin of 55.46%[23] - The cosmetics segment saw significant growth, with revenue reaching CNY 419 million in Q1 2022, a year-on-year increase of 95.31% and a gross margin of 61.56%[22] - The health real estate segment experienced a decline, with a signed contract amount of CNY 777 million in Q1 2022, down 75.6% year-on-year[19] - The decrease in net profit was mainly due to a reduction in real estate business revenue[10] - The company’s non-real estate business revenue is steadily increasing, with new projects in construction management and commercial management expanding its portfolio[22] Research and Development - Research and development expenses for Q1 2022 were ¥22,342,527.54, a slight decrease from ¥23,263,647.47 in Q1 2021[39] - The company received government subsidies amounting to ¥7,738,651.98, primarily related to pharmaceutical research and development[8] Strategic Direction - The company plans to continue its strategic transformation towards the health industry, moving away from real estate[19]